REMARKS/ARGUMENTS

Discussion of Specification and Claim Amendments

The specification has been amended to include a reference to [SEQ ID NO: 1] or [SEQ ID NO:2] as appropriate, or to correct obvious typographical errors. The amendment to the paragraph beginning at page 7, line 4 [SEQ ID NO: 2] is supported by the correct formula IV spelled out immediately following the sequence; from page 7, lines 20-21 and the synthetic scheme at page 5. Claim 1 has been amended to improve the form. Claim 6 has been amended to remove "prophylaxis".

No new matter has been added.

Discussion of Rejections

A. Non-enablement -

Applicants have amended Claim 6 to remove prophylaxis. Accordingly, the non-enablement rejection has been obviated, and therefore, the rejection should be withdrawn.

B. Indefiniteness -

Applicants have amended claim 1 as discussed, which should remove the indefiniteness rejection.

C. Sequence Listing -

Applicants herewith submit a replacement Sequence Listing. Accordingly, the requirement has been fulfilled. Applicants request entry of the replacement Sequence Listing.

Conclusion

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Date: July 14, 2008

Respectfully submitted,

Xavier Fillai, Reg. No. 39,799

LEYDIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900

180 North Stetson Avenue

Chicago, Illinois 60601-6731

(312) 616-5600 (telephone)

(312) 616-5700 (facsimile)